[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer)
Filing Explained
No securities transaction is disclosed; the stated action is adding this report to the listed S-8 and F-3 registration statements.
As a Form 6-K, this report furnishes interim information from a foreign private issuer and states that it is being incorporated by reference into listed Form S-8 and Form F-3 registration statements.
The disclosed action changes the contents of those registration statements; this filing itself does not disclose an issuance or sale of securities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-163
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026
Alterity Therapeutics Limited
(Name of Registrant)
Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)
ALTERITY THERAPEUTICS LIMITED
(a development stage enterprise)
The following exhibits are submitted:
|
99.1 |
Change of Director's Interest Notice - Marks |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Alterity Therapeutics Limited |
||
|
By: |
/s/ Julian Babarczy |
|
|
Julian Babarczy |
||
|
Chairman |
||
Date: September 2, 2026
Exhibit 99.1
